A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China
Abstract. Background:. There were few studies on real-world data about autologous hematopoietic stem cell transplantation (auto-HSCT) or allogeneic HSCT (allo-HSCT) in peripheral T-cell lymphoma (PTCL). This study aimed to investigate the clinical outcomes of patients who received auto-HSCT or allo-...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2021-07-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000001575 |
| _version_ | 1819141930003464192 |
|---|---|
| author | Zhen-Yang Gu Yu-Jun Dong Xiao-Rui Fu Nai-Nong Li Yao Liu Xiao-Xiong Wu Yi-Ni Wang Yu-Hang Li Han-Yun Ren Ming-Zhi Zhang Xiao-Fan Li Mai-Hong Wang Ya-Mei Wu Dai-Hong Liu Zhao Wang Liang-Ding Hu Wen-Rong Huang Peng Lyu |
| author_facet | Zhen-Yang Gu Yu-Jun Dong Xiao-Rui Fu Nai-Nong Li Yao Liu Xiao-Xiong Wu Yi-Ni Wang Yu-Hang Li Han-Yun Ren Ming-Zhi Zhang Xiao-Fan Li Mai-Hong Wang Ya-Mei Wu Dai-Hong Liu Zhao Wang Liang-Ding Hu Wen-Rong Huang Peng Lyu |
| author_sort | Zhen-Yang Gu |
| collection | DOAJ |
| description | Abstract. Background:. There were few studies on real-world data about autologous hematopoietic stem cell transplantation (auto-HSCT) or allogeneic HSCT (allo-HSCT) in peripheral T-cell lymphoma (PTCL). This study aimed to investigate the clinical outcomes of patients who received auto-HSCT or allo-HSCT in China.
Methods:. From July 2007 to June 2017, a total of 128 patients who received auto-HSCT (n = 72) or allo-HSCT (n = 56) at eight medical centers across China were included in this study. We retrospectively collected their demographic and clinical data and compared the clinical outcomes between groups.
Results:. Patients receiving allo-HSCT were more likely to be diagnosed with stage III or IV disease (95% vs. 82%, P = 0.027), bone marrow involvement (42% vs. 15%, P = 0.001), chemotherapy-resistant disease (41% vs. 8%, P = 0.001), and progression disease (32% vs. 4%, P < 0.001) at transplantation than those receiving auto-HSCT. With a median follow-up of 30 (2–143) months, 3-year overall survival (OS) and progression-free survival (PFS) in the auto-HSCT group were 70%(48/63) and 59%(42/63), respectively. Three-year OS and PFS for allo-HSCT recipients were 46%(27/54) and 44%(29/54), respectively. There was no difference in relapse rate (34%[17/63] in auto-HSCT vs. 29%[15/54] in allo-HSCT, P = 0.840). Three-year non-relapse mortality rate in auto-HSCT recipients was 6%(4/63) compared with 27%(14/54) for allo-HSCT recipients (P = 0.004). Subanalyses showed that patients with lower prognostic index scores for PTCL (PIT) who received auto-HSCT in an upfront setting had a better outcome than patients with higher PIT scores (3-year OS: 85% vs. 40%, P = 0.003). Patients with complete remission (CR) undergoing auto-HSCT had better survival (3-year OS: 88% vs. 48% in allo-HSCT, P = 0.008). For patients beyond CR, the outcome of patients who received allo-HSCT was similar to that in the atuo-HSCT group (3-year OS: 51% vs. 46%, P = 0.300).
Conclusions:. Our study provided real-world data about auto-HSCT and allo-HSCT in China. Auto-HSCT seemed to be associated with better survival for patients in good condition (lower PIT score and/or better disease control). For patients possessing unfavorable characteristics, the survival of patients receiving allo-HSCT group was similar to that in the auto-HSCT group. |
| first_indexed | 2024-12-22T12:02:16Z |
| format | Article |
| id | doaj.art-3feb198c594d4ca7b1d968b927c70681 |
| institution | Directory Open Access Journal |
| issn | 0366-6999 2542-5641 |
| language | English |
| last_indexed | 2024-12-22T12:02:16Z |
| publishDate | 2021-07-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj.art-3feb198c594d4ca7b1d968b927c706812022-12-21T18:26:34ZengWolters KluwerChinese Medical Journal0366-69992542-56412021-07-01134131584159210.1097/CM9.0000000000001575202107050-00012A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in ChinaZhen-Yang GuYu-Jun DongXiao-Rui FuNai-Nong LiYao LiuXiao-Xiong WuYi-Ni WangYu-Hang LiHan-Yun RenMing-Zhi ZhangXiao-Fan LiMai-Hong WangYa-Mei WuDai-Hong LiuZhao WangLiang-Ding HuWen-Rong HuangPeng LyuAbstract. Background:. There were few studies on real-world data about autologous hematopoietic stem cell transplantation (auto-HSCT) or allogeneic HSCT (allo-HSCT) in peripheral T-cell lymphoma (PTCL). This study aimed to investigate the clinical outcomes of patients who received auto-HSCT or allo-HSCT in China. Methods:. From July 2007 to June 2017, a total of 128 patients who received auto-HSCT (n = 72) or allo-HSCT (n = 56) at eight medical centers across China were included in this study. We retrospectively collected their demographic and clinical data and compared the clinical outcomes between groups. Results:. Patients receiving allo-HSCT were more likely to be diagnosed with stage III or IV disease (95% vs. 82%, P = 0.027), bone marrow involvement (42% vs. 15%, P = 0.001), chemotherapy-resistant disease (41% vs. 8%, P = 0.001), and progression disease (32% vs. 4%, P < 0.001) at transplantation than those receiving auto-HSCT. With a median follow-up of 30 (2–143) months, 3-year overall survival (OS) and progression-free survival (PFS) in the auto-HSCT group were 70%(48/63) and 59%(42/63), respectively. Three-year OS and PFS for allo-HSCT recipients were 46%(27/54) and 44%(29/54), respectively. There was no difference in relapse rate (34%[17/63] in auto-HSCT vs. 29%[15/54] in allo-HSCT, P = 0.840). Three-year non-relapse mortality rate in auto-HSCT recipients was 6%(4/63) compared with 27%(14/54) for allo-HSCT recipients (P = 0.004). Subanalyses showed that patients with lower prognostic index scores for PTCL (PIT) who received auto-HSCT in an upfront setting had a better outcome than patients with higher PIT scores (3-year OS: 85% vs. 40%, P = 0.003). Patients with complete remission (CR) undergoing auto-HSCT had better survival (3-year OS: 88% vs. 48% in allo-HSCT, P = 0.008). For patients beyond CR, the outcome of patients who received allo-HSCT was similar to that in the atuo-HSCT group (3-year OS: 51% vs. 46%, P = 0.300). Conclusions:. Our study provided real-world data about auto-HSCT and allo-HSCT in China. Auto-HSCT seemed to be associated with better survival for patients in good condition (lower PIT score and/or better disease control). For patients possessing unfavorable characteristics, the survival of patients receiving allo-HSCT group was similar to that in the auto-HSCT group.http://journals.lww.com/10.1097/CM9.0000000000001575 |
| spellingShingle | Zhen-Yang Gu Yu-Jun Dong Xiao-Rui Fu Nai-Nong Li Yao Liu Xiao-Xiong Wu Yi-Ni Wang Yu-Hang Li Han-Yun Ren Ming-Zhi Zhang Xiao-Fan Li Mai-Hong Wang Ya-Mei Wu Dai-Hong Liu Zhao Wang Liang-Ding Hu Wen-Rong Huang Peng Lyu A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China Chinese Medical Journal |
| title | A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China |
| title_full | A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China |
| title_fullStr | A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China |
| title_full_unstemmed | A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China |
| title_short | A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China |
| title_sort | multicenter retrospective study on the real world outcomes of autologous vs allogeneic hematopoietic stem cell transplantation for peripheral t cell lymphoma in china |
| url | http://journals.lww.com/10.1097/CM9.0000000000001575 |
| work_keys_str_mv | AT zhenyanggu amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yujundong amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT xiaoruifu amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT nainongli amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yaoliu amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT xiaoxiongwu amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yiniwang amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yuhangli amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT hanyunren amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT mingzhizhang amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT xiaofanli amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT maihongwang amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yameiwu amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT daihongliu amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT zhaowang amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT liangdinghu amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT wenronghuang amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT penglyu amulticenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT zhenyanggu multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yujundong multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT xiaoruifu multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT nainongli multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yaoliu multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT xiaoxiongwu multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yiniwang multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yuhangli multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT hanyunren multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT mingzhizhang multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT xiaofanli multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT maihongwang multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT yameiwu multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT daihongliu multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT zhaowang multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT liangdinghu multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT wenronghuang multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina AT penglyu multicenterretrospectivestudyontherealworldoutcomesofautologousvsallogeneichematopoieticstemcelltransplantationforperipheraltcelllymphomainchina |